Navigation Links
Onset Dermatologics Launches HylatopicPlus-Aurstat™ Kit
Date:2/22/2011

CUMBERLAND, R.I., Feb. 22, 2011 /PRNewswire/ -- Onset Dermatologics, a PreCision Dermatology company and a leader in developing and commercializing novel, prescription products for improving skin health, today announced the launch of the HylatopicPlus-Aurstat™ Kit.  The kit provides two products within one package: HylatopicPlus™ Emollient Foam indicated to manage and relieve burning, itching and pain that can accompany skin dermatoses such as atopic dermatitis (eczema) and Aurstat™ Skin & Wound HydroGel, which is used to relieve skin irritation, minor abrasions and lacerations — and also can be used on intact skin.  

"We believe that the newly launched HylatopicPlus-Aurstat™ Kit provides physicians and patients greater convenience when skin barrier dysfunction and S. aureus colonization are present in the same patient," said Doug Abel, General Manager of Onset Dermatologics.  "The kit provides two therapies in one prescription for a single co-pay, which may improve patient adherence to physician instructions and thus, result in improved clinical outcomes."

HylatopicPlus™ Emollient Foam is formulated to rapidly hydrate the stratum corneum (the top layer of the epidermis) and provide a semi-permeable barrier that protects against irritants and excessive water loss through the skin. HylatopicPlus™ incorporates hyaluronic acid to deliver a blend of physiologic lipids, including ceramide, to restore healthy barrier function. HylatopicPlus™ has been clinically proven to improve the symptoms of atopic dermatitis.

Aurstat™ HydroGel is intended for over-the-counter use on minor skin abrasions and lacerations — and for use on intact skin. Aurstat™ contains a unique shelf-stable formulation of hypochlorous acid in hydrogel form. In a laboratory setting, Aurstat™ killed 99.99% of Staphylococcus aureus (S. aureus) within 30 seconds post-application.   Aurstat™ HydroGel is non-irritating and can be safely used around the eyes, nose and mouth.

The HylatopicPlus-Aurstat™ Kit is now available in the U.S. by prescription only.

Important Safety Information for HylatopicPlus™ Emollient Foam

HylatopicPlus™ is contraindicated in persons with a known hypersensitivity to any of the components of the formulation. If clinical signs of infection are present, appropriate treatment should be initiated; use of HylatopicPlus™ Emollient Foam may be continued

during the anti-infective therapy.

About Onset Dermatologics

Onset Dermatologics (www.onsetdermatologics.com) is dedicated to providing new, optimized, innovative, practical and cost-effective pharmaceutical products to the healthcare market in an effort to improve the quality of life for patients. The company markets 11 products based on its proprietary Delevo® foam technology platform that is designed to deliver enhanced penetration of proven active ingredients while improving patient compliance.

About PreCision Dermatology, Inc.

Headquartered in Cumberland RI, PreCision Dermatology is a fully-integrated dermatology company with a mission to deliver innovative therapies to doctors and patients that demonstrably improve the care of skin. PreCision Dermatology will expand quickly through acquisitions, in-licensing, co-marketing opportunities as well as internally generated therapies.  


'/>"/>
SOURCE Onset Dermatologics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Treatment for Prescription Drug Addiction and Painkiller Abuse has Risen Sharply Since Onset of Financial Crisis, Reflecting Uncertainty About Economy
2. First Patient Enrolled in Multi-Center Clinical Trial of the CorMatrix® ECM® for Pericardial Closure to Reduce the Incidence of New Onset Postoperative Atrial Fibrillation
3. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
4. Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa®
5. Depression and Cognitive Disorders: at the Onset of Alzheimers Disease
6. CorMatrix Receives FDA IDE Approval to Begin Prospective, Randomized Evaluation of New Onset Postoperative Atrial Fibrillation in Subjects Receiving the CorMatrix® ECM™ for Pericardial Closure
7. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
8. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
9. FDA Approves New Treatment for Late-Onset Pompe Disease
10. Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects
11. New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... KALAMAZOO, Michigan , USA, March 29, 2017 /PRNewswire/ ... a Company that Cares by People magazine, in partnership ... out of 50 companies on the list. This list ... employees that have succeeded in business while also demonstrating ... and the environment.  To determine the ...
(Date:3/29/2017)... FinancialBuzz.com News Commentary  ... Data published in a research report by Grand View Research, Inc., projects ... 55.8 billion by 2025. The projection takes into consideration the continuous successful ... more open approach towards cannabis products around the world. In 2016, states ... North Dakota , Ohio , and ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced ... Software Market Outlook: 2016-2022" report to their offering. ... The global patient safety ... of delivery, end-user, and geography. Patient safety has ... globe. The field has developed significantly in the last decade and ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul ... , WHAT: , Medical doctors and PhD scientists will speak to the press on ... Trump in support of an independent vaccine safety commission. , WHERE: , Zenger ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... The ... MHA, FRBMA, has begun to serve as its new executive director. Mr. Still was ... Executive Search Committee. , “Bob, as he is known to our members, has ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... physicians, Paul Yost, will begin serving as new board chair for Orange County ... Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, which ...
(Date:3/28/2017)... ... 2017 , ... Neurotechnology , a provider of high-precision ... tracking products: the new NCheck Cloud Bio Attendance cloud-based service and the updated  ... recognition to enable users to check in and out from anywhere via the ...
(Date:3/28/2017)... MA (PRWEB) , ... March 28, 2017 , ... ... for direct measurement of corrosive ions found in power plant water and steam. ... components such as turbines and boilers, leading to extensive maintenance and unplanned shutdowns. ...
Breaking Medicine News(10 mins):